1. A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer. (9th September 2022) Authors: Xu, Yinghui; Wang, Xu; Sun, Chao; Gao, Zhiru; He, Hua; Qiu, Shi; Guo, Ye; Ma, Xiaohui; Song, Junya; Ma, Kewei Journal: Cancer medicine Issue: Volume 12:Number 3(2023) Page Start: 2979 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease. (September 2020) Authors: Sun, Mengyao; Xu, Yinghui; He, Hua; Zhang, Li; Wang, Xu; Qiu, Qing; Sun, Chao; Guo, Ye; Qiu, Shi; Ma, Kewei Journal: International journal of infectious diseases Issue: Volume 98(2020) Page Start: 334 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Altered brain structural topological properties in Parkinson's disease with levodopa-induced dyskinesias. (October 2019) Authors: Wang, Lina; Wang, Min; Si, Qianqian; Yuan, Yongsheng; Ma, Kewei; Gan, Caiting; Zhang, Kezhong Journal: Parkinsonism & related disorders Issue: Volume 67(2019) Page Start: 36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. An Individual Risk Prediction Model for Lung Cancer Based on a Study in a Chinese Population. Issue 1 (January 2015) Authors: Wang, Xu; Ma, Kewei; Cui, Jiuwei; Chen, Xiao; Jin, Lina; Li, Wei Journal: Tumori Issue: Volume 101:Issue 1(2015) Page Start: 16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870). (November 2022) Authors: Lu, Shun; Cheng, Ying; Zhou, Jianying; Wang, Mengzhao; Zhao, Jun; Wang, Baocheng; Chen, Gongyan; Feng, Jifeng; Ma, Zhiyong; Wu, Lin; Wang, Changli; Ma, Kewei; Zhang, Shucai; Liang, Jun; Song, Yong; Wang, Jie; Wu, Yi-Long; Li, Ang; Huang, Yizhi; Chang, Jianhua Journal: Therapeutic advances in medical oncology Issue: Volume 14(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China. Issue 1 (1st December 2021) Authors: Zou, Zihua; Hao, Xuezhi; Zhang, Cuiying; Li, Haojing; Dong, Guilan; Peng, Yumei; Ma, Kewei; Guo, Ye; Shan, Li; Zhang, Yan; Liang, Li; Gu, Yangchun; Xing, Puyuan; Li, Junling Journal: Thoracic cancer Issue: Volume 13:Issue 1(2022) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Coexistence of atypical adenomatous hyperplasia, minimally invasive adenocarcinoma and invasive adenocarcinoma: Gene mutation analysis. Issue 5 (14th January 2021) Authors: Song, Junya; Xu, Yinghui; Yang, Zhiguang; Liu, Yunpeng; Zhang, Peng; Wang, Xu; Sun, Chao; Guo, Ye; Qiu, Shi; Shao, Guoguang; Ma, Kewei Journal: Thoracic cancer Issue: Volume 12:Issue 5(2021) Page Start: 693 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions. Issue 3 (27th December 2021) Authors: Sun, Mengyao; Wang, Xu; Xu, Yinghui; Sun, Chao; Guo, Ye; Qiu, Shi; Zhao, Renshan; Zhu, Wenhao; Ma, Kewei Journal: Thoracic cancer Issue: Volume 13:Issue 3(2022) Page Start: 514 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. Issue 1 (January 2020) Authors: Yang, Yunpeng; Zhou, Jianya; Zhou, Jianying; Feng, Jifeng; Zhuang, Wu; Chen, Jianhua; Zhao, Jun; Zhong, Wei; Zhao, Yanqiu; Zhang, Yiping; Song, Yong; Hu, Yi; Yu, Zhuang; Gong, Youling; Chen, Yuan; Ye, Feng; Zhang, Shucai; Cao, Lejie; Fan, Yun; Wu, Gang Journal: Lancet Issue: Volume 8:Issue 1(2020) Page Start: 45 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Follow‐up of an occult tuberculosis scar cancer after resection of metastatic lesions. Issue 8 (22nd June 2020) Authors: Sun, Mengyao; Xu, Yinghui; Wang, Xu; Sun, Chao; Guo, Ye; Shao, Guoguang; Yang, Zhiguang; Liu, Yunpeng; Zhang, Peng; Qiu, Shi; Ma, Kewei Journal: Thoracic cancer Issue: Volume 11:Issue 8(2020) Page Start: 2347 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗